Document:

EX-10.19

 Exhibit 10.19 

EXECUTION COPY 
 SECOND
AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 
 THIS SECOND AMENDMENT is entered into as of this 10th day of January, 2014 and serves to amend the Exclusive Channel Collaboration Agreement entered into by and between Intrexon Corporation (“Intrexon”) and Fibrocell Science, Inc.
(“Fibrocell”), on October 5, 2012 and first amended on June 28, 2013 (as amended, the “Agreement”). All capitalized terms not defined herein shall have the meaning set forth in the Agreement. 

WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the identification, design and production of
genetically modified cells and DNA vectors, and the control of expression of proteins and bioactive RNA species; and 
 WHEREAS,
pursuant to the Agreement, Fibrocell is currently Intrexon’s exclusive channel collaborator with the right to use Intrexon technology to research, develop and commercialize products for use in a specific Field (as defined in the Agreement);
and 
 WHEREAS, Fibrocell now desires to broaden the scope of its rights under the Agreement in order to research, develop and
commercialize products for use in certain additional areas as more fully described below, and Intrexon is willing to grant such additional rights in exchange for certain compensation as more fully described below. 

NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained herein, the Parties hereby agree to amend the
Agreement pursuant to Section 12.7 thereof as follows: 
  

	 	1.	 Section 1.29 of the Agreement is hereby replaced in its entirety with the following: 

“1.29 “Field” means, as of the Effective Date and irrespective of whether such requires regulatory approval, (i) the
enhanced production and purification of non-genetically modified human autologous fibroblasts for use in all aesthetic and therapeutic indications; (ii) the enhanced production and purification of non-genetically modified human autologous dermal cells for use in aesthetic and therapeutic treatment of dermal, vocal cord, and periodontal indications; (iii) the development of genetically modified autologous
human fibroblasts for use in all aesthetic and therapeutic indications where an autologous fibroblast itself is the principal effector of the product in contrast to the use of autologous fibroblasts as the source of expression of a systemically
available therapeutic protein in which that protein (and not the fibroblast per se) is the principal therapeutic effector; (iv) the development of genetically modified autologous human dermal cells for aesthetic and therapeutic treatment of
dermal, vocal cord, and periodontal indications; (v) autologous human fibroblasts genetically modified to express a therapeutic protein and/or bioactive RNA for the treatment of autoimmune and
non-infectious inflammatory disorders that manifest in cutaneous tissues, fascia and/or muscle, and (vi) autologous human fibroblasts genetically modified to express bioactive Tenascin X locally to
correct connective tissue disorders. For clarity, the “Field” does not include inductive pluripotent cell products that are derived from autologous fibroblasts or dermal cells or products that are subject to an existing Intrexon
collaboration.” 

	 	2.	 In partial consideration for the additional rights granted to Fibrocell hereunder, Fibrocell shall issue to
Intrexon, as an additional access fee for commercial license rights to the Intrexon IP granted hereunder, certain shares of the common stock of Fibrocell (the “Supplemental Access Fee”). The Supplemental Access Fee will be that number of
shares of Fibrocell common stock (the “Supplemental Access Fee Shares”) having a value equaling approximately $5,000,000, and such shares’ issuance will occur pursuant to the terms of a Supplemental Stock Issuance Agreement of even
date herewith (the “Issuance Agreement”). Provided that all closing conditions for the Supplemental Access Fee Shares (as defined in the Issuance Agreement) that are within the reasonable control of Intrexon have been satisfied or waived,
the issuance of the Supplemental Access Fee Shares is a condition subsequent to the effectiveness of this Amendment. 

  

	 	3.	 The Parties hereby acknowledge that the Supplemental Access Fee Shares shall constitute “Registrable
Securities” as defined in that certain Registration Rights Agreement, dated October 5, 2012, between the Parties. 

  

	 	4.	 Fibrocell hereby represents and warrants to Intrexon that, as of the date of this Amendment:

  

	 	a.	 Corporate Power. Fibrocell is duly organized and validly existing under the laws of Delaware and has
full corporate power and authority to enter into this Amendment and to carry out the provisions hereof. 

  

	 	b.	 Due Authorization. Fibrocell is duly authorized to execute and deliver this Amendment and to perform its
obligations hereunder, and the person executing this Amendment on Fibrocell’s behalf has been duly authorized to do so by all requisite corporate action. 

 

	 	5.	 Intrexon hereby represents and warrants to Fibrocell that, as of the date of this Amendment:

  

	 	a.	 Corporate Power. Intrexon is duly organized and validly existing under the laws of Virginia and has full
corporate power and authority to enter into this Amendment and to carry out the provisions hereof. 

  

	 	b.	 Due Authorization. Intrexon is duly authorized to execute and deliver this Amendment and to perform its
obligations hereunder, and the person executing this Amendment on Intrexon’s behalf has been duly authorized to do so by all requisite corporate action. 

  

	 	6.	 The Parties agree that the public announcement of the execution of this Amendment shall be substantially in the
form of a press release and/or the filing of a Form 8-K by Fibrocell, which shall be mutually agreed to by the Parties. 

 

	 	7.	 All other terms and conditions of the Agreement remain in full force and effect. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Second Amendment to Exclusive Channel
Collaboration Agreement by authorized representatives as of the date written above. 
  

			
	INTREXON CORPORATION
		
	By:	 	/s/ Gregory Frost
	Name:	 	Gregory Frost
	Title:	 	SVP Health Sector

  

			
	FIBROCELL SCIENCE, INC.
		
	By:	 	/s/ David Pernock
	Name:	 	David Pernock
	Title:	 	CEOEX-10.20

 Exhibit 10.20 

 
 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
 February 19, 2020 

Fibrocell Science, Inc. 
 c/o Castle Creek Biosciences, Inc. 

6 Century Blvd. 
 Parsippany, NJ 07054 

Attention: CEO 
  

	Re:	 “Exclusive Channel Collaboration Agreement” executed Oct. 5, 2012 (as subsequently amended,
the “ECC”) by and between Fibrocell Science, Inc. (“Fibrocell”) and Intrexon Corporation (“Intrexon”) 

Dear Sir: 
 This letter sets forth and memorializes the various
points of mutual agreement reached between Precigen and Fibrocell with respect to the termination of the ECC, the conversion of the ECC into a product license between Fibrocell and Precigen with regard to the Retained Products and related amendments
and modifications of the ECC. Please note that, per our recent public announcement, Intrexon has officially been renamed Precigen, Inc. (“Precigen”). Unless otherwise specified, references to Fibrocell in this letter shall refer to both
Fibrocell and its parent, Castle Creek Biosciences, Inc. (“CCB”), and references to Precigen in this letter shall be deemed to encompass references to Intrexon prior to its having been renamed Precigen. Precigen and Fibrocell are sometimes
referred to herein collectively as the “Parties” and individually as a “Party”. Capitalized terms not otherwise defined in this letter shall have the meaning set forth in the ECC to the extent such are defined therein. 

In consideration for the mutual covenants and agreements set forth in this letter, together with additional consideration, the receipt and sufficiency of
which are hereby acknowledged by the Parties, the Parties mutually agree as follows: 
  

	1)	 The Parties agree to work together in good faith to negotiate, document and execute a mutually agreed upon
definitive termination and modification agreement between the Parties (the “Termination and Modification Agreement”) with respect to the termination of the ECC, the conversion of the ECC into a product license between Fibrocell with regard
to the Retained Products and related amendments and modifications of the ECC, with the Parties’ intent being to enter into the Termination and Modification Agreement within thirty (30) days after the date of this letter to amend and modify
the ECC as necessary and appropriate in order to clarify the surviving rights and obligations of the Parties, including the surviving rights and licenses in favor of Fibrocell with respect to the Retained Products, consistent with this letter.

  

	2)	 Without limiting the generality of the foregoing, the Parties hereby agree as follows below:

  
 Page 1 

 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
  

 (a) Fibrocell’s FCX-007 and FCX-013 are each Fibrocell Products as defined in the ECC. 
 (b) The definition for “Field” in
Section 1.29 of the ECC is amended and restated to read in its entirety as follows: 
 “1.29 “Field” means, as of
the Effective Date and irrespective of whether such requires regulatory approval, the delivery of autologous human fibroblasts genetically modified to express COL7 and/or MMP-1 for the treatment of Scleroderma
and Epidermolysis Bullosa.” 
 (c) Irrespective of whether one or both of Fibrocell’s
FCX-007 or FCX-013 fail to meet the requirements of any one of ECC Sections 10.4(a)(i) through 10.4(a)(v) at the effective time of the Termination and Modification
Agreement, each of FCX-007 and FCX-013 will respectively be deemed a Retained Product under the ECC, and such Fibrocell Products shall constitute the only Retained
Products under the ECC. 
 (d) There are no Reverted Products or Improved Products as defined in the ECC. 

(e) The Termination and Modification Agreement shall provide, among other things, that the ECC shall be terminated on the effective time of the
Termination and Modification Agreement, subject to the surviving rights and licenses in favor of Fibrocell with respect to the Retained Products after such termination (including, but not limited to, the surviving rights and licenses in favor of
Fibrocell pursuant to Section 10.4 (incorporating with respect to the Retained Products the license and sublicense rights of Sections 3.1 and 3.2) to continue the clinical development and Commercialization of the Retained Products in the Field
in the Territory following such termination, which rights and licenses are contingent upon Fibrocell’s compliance with the payment provisions in ECC Article 5 (including, the revenue sharing obligations set forth in Section 5.3 thereof),
and with a continuing obligation for Fibrocell to use in accord with ECC Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and Commercialize any Retained Products, and with all other provisions of the ECC that survive such termination). 

(f) Notwithstanding Section 10.5 of the ECC, Sections 3.5, 3.6 and 6.3 of the ECC shall survive termination of the ECC solely to the
extent that Fibrocell continues to comply with the payment provisions in ECC Article 5 (including, the revenue sharing obligations set forth in Section 5.3 thereof), and with a continuing obligation for Fibrocell to use in accord with ECC
Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and Commercialize any Retained Products, and with all other provisions of the ECC that survive such termination.  

(g) Section 3.8 is hereby modified and amended by deleting the phrase “during the Term” at the end of the first sentence.
Further, notwithstanding Section 10.5 of the ECC, Section 3.8 of the ECC as so modified shall survive termination of the ECC solely with respect to, and solely to the extent there remain, Retained Products. For clarity, 

  
 Page 2 

 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
  

 however, Precigen shall retain rights to its future veledimex drug master files (subject to
the granting of rights of reference as set forth in this letter and Attachment A).  
 (h) Notwithstanding Section 10.5 of
the ECC, such Section 10.4(b) of the ECC (including the first sentence of which as modified by this letter and the Termination and Modification Agreement) shall survive termination of the ECC. 

(i) Notwithstanding Section 10.5 of the ECC, Sections 7.5(a) and 7.5(b) of the ECC shall not survive termination of the ECC. 

(j) As of the effective time of the Termination and Modification Agreement, neither Party shall have any obligation under the ECC to develop
and/or Commercialize any product other than the Retained Products. 
  

	3)	 Precigen personnel will provide immediate CMC technical and project management work toward resolving certain
veledimex batch manufacture and expiration issues for Fibrocell in general accordance with the plan set forth in Attachment A and with the intention of meeting, to the extent reasonably possible, the known clinical trial timing issues for
Fibrocell. Such work will be done at Precigen’s cost for Precigen’s internal personnel’s time expended on the project and in preparing drug master files (collectively, the “DMF”), while Fibrocell will remain responsible for
any third party costs (including manufacturing, service providers and reasonable travel) incurred during this process for the benefit of Fibrocell. The Parties will share in the data and intellectual property generated by work performed pursuant to
Attachment A consistent with the terms of the ECC. After completion of Precigen’s work contemplated under Attachment A, and subject to payment by Fibrocell of third party costs under paragraph 2 above, Precigen will grant
Fibrocell an irrevocable right of cross-reference to Precigen’s DMF for use in connection with FCX-013 and provide specified technology transfer. Thereafter, Fibrocell shall assume all responsibility for
future manufacture of drug product and drug substance for Fibrocell Products. 

 Please confirm Fibrocell’s agreement to the
foregoing terms by signing this letter in the space provided below and returning one executed copy to us, whereupon this letter will be deemed a mutually executed and binding agreement between Precigen and Fibrocell. In the event the Parties are
unable to enter into the Termination and Modification Agreement within thirty days following the execution of this letter agreement, then absent agreement by the Parties, the obligations under this letter agreement shall be terminated and the rights
and obligations of the Parties with respect to the ECC shall remain unchanged. 

  
 Page 3 

 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
  

 We continue to look forward to the progress and success of Fibrocell’s clinical programs for FCX-007 and FCX-013, and thank you for your attention to this matter. 

Sincerely, 
 PRECIGEN, INC. 

/s/ Donald P.
Lehr                             

Donald P. Lehr 
 Chief Legal Officer 

301-556-9809  

cc (email): Helen Sabzevari, President and CEO, Precigen, Inc. 

cc (email): John Maslowski, CEO, Fibrocell Science, Inc. 
  

			
		 	Acknowledged and agreed on behalf of
		 	Fibrocell Science, Inc.:
		
	signed:	 	/s/ John M. Maslowski
	name, and title:	 	John M. Maslowski
	date:	 	20 Feb 2020

  
 Page 4 

 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
  

 Attachment A 

Precigen will provide Fibrocell with the following drug product and drug substance manufacturing and related CMC support activities and deliverables: 

 

	 	1.	 In good faith, Precigen has already provided, at no cost to Fibrocell, a critical expiration extension memo
(for expiry May 2020) to Jeremy Cress of CCB on February 6, 2020. 

  

	 	2.	 Precigen will, at no cost to Fibrocell for Precigen’s internal personnel time, conduct a 24-month time point pull in March 2020 and issue an extension memo to Fibrocell based on the results thereof on or before the expiration of the prior May, 2020 extension, with the goal of demonstrating a new
expiration of drug product INXN- 1001 Hard Gelatin Capsules, 40mg (Solutol) batch QB170160/1 of November 6, 2020. If such stability testing results do not support such extension, Precigen will provide to Fibrocell all documentation and data
generated during such failed stability testing. Any costs for third party service providers shall be borne directly by Fibrocell, and any travel expenses reasonably incurred by Precigen shall be reimbursed by Fibrocell upon monthly invoicing for the
same. 

  

	 	3.	 Precigen will coordinate with third party service providers to initiate, and oversee their respective
performance toward, the manufacture of a new batch of the Solutol formulation before April 27, 2020 to serve as a replacement for the existing Drug Substance batch (4157.E.15.1.501). All such manufactured material will be solely
owned by Fibrocell. The costs for the third party service provider and manufacturers shall be borne and paid directly by Fibrocell, and any travel expenses reasonably incurred by Precigen shall be reimbursed by Fibrocell upon monthly invoicing for
the same. In good faith, Precigen has begun coordination with Lonza/Capsugel Ploermel to attempt scheduling of a replacement Batch manufacturing slot, but needs final approval from Fibrocell to generate a formal proposal and respective cost quotes
before Feb. 19, 2020, which proposal shall be shared with Fibrocell once received. Lonza/Capsugel Ploermel have indicated, subject to the meeting of timetables by the Parties (including the foregoing approval from Fibrocell) that the production will
meet Fibrocell’s deadlines. Based solely upon prior experience manufacturing batches of veledimex and incorporating reasonably projected cost increases relative to prior production batches, Precigen estimates that the third party costs for such
(excluding travel) will be: 

  

					
		 	a. Shipment costs	  	20,000 Euros (estimated)
		 	b. Manufacture	  	135,000 Euros (estimated)
		 	c. ICH Stability	  	160,000 Euros (estimated)
		 	d. Reference Materials	  	75,000 Euros (estimated)

  

	 	4.	 Precigen will execute a Quality Audit of Solutol activities at the Ploermel site and one representative of
Fibrocell will be invited to attend. In the event there are findings resulting from such an audit, Fibrocell will be entitled to review and provide Precigen with comments thereon for reasonable consideration, provided, however, that if such findings
are specific to FCX-007 and FCX-013, Fibrocell will also be entitled to provide direction on the correction of such findings. No audit of Solutol related activities has
been previously conducted. These activities would be targeted to be performed in 3Q 2020 and Lonza/Capsugel Ploermel are aware of the requirement from Precigen’s pre-existing Quality Agreement. However,
Fibrocell shall be responsible for conducting all quality review and release of all materials produced in the above new batch. 

  
 Page 5 

 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
  

	 	5.	 Precigen agrees to invite representatives of Fibrocell to a kick off meeting to be held reasonably promptly
following the Effective Date of this letter, and thereafter to reasonably frequent update meetings with Precigen personnel and, where appropriate, third party providers. Fibrocell will be provided with copies of all relevant synthesis proposals and
protocols and relevant reports received from such third parties. 

  

	 	6.	 In conjunction with the above activities, Precigen shall engage in tech transfer for the benefit of Fibrocell
to enable Fibrocell to engage in manufacturing activities directly, including as follows below. 

  

	 	a.	 Precigen and Fibrocell will reasonably cooperate to proceed within the spirit and intent of this letter and
Attachment A with regard to executing new contracts with respective third parties, or alternatively submitting work orders under existing contracts, with the goals of meeting the deadlines set forth above. Where new agreements are required to
execute a project task under this Attachment A, Fibrocell will be included as a party to the agreement when such will not cause problematic delays given the timelines above. 

 

	 	b.	 Precigen shall deliver to Fibrocell the following information and data reasonably necessary for Fibrocell to
conduct future drug product and drug substance manufacturing tasks independently of Precigen and to contract directly with third parties with respect such. 

  

	 	i.	 The Capsugel documentation relating to the Solutol formulation. 

 

	 	ii.	 Executed protocols and reports relating to veledimex drug substance and drug product. 

 

	 	iii.	 Previous analytical qualifications and methods and protocols for the release of drug substance/product.

  

	 	iv.	 Stability protocols, data and reports. 

 

	 	v.	 Full batch records for the new batch under paragraph 3 above. 

 

	 	vi.	 Route A chemistry documentation. 

 

	 	vii.	 A letter providing to Fibrocell with respect to the Retained Products an irrevocable right of reference to
Precigen’s (to be filed) drug master files for veledimex and formulations of veledimex upon their respective filing by Precigen. 

  

	 	7.	 Precigen estimates that the above activities will require 7-8 FTE
months of Precigen personnel time, including all planning activities, coordination with Lonza, travel and oversight as well as a formal audit. 

  

	 	8.	 Precigen will allocate to Fibrocell fifty percent (50%) of any material remaining of expired drug substance
batch 4157.E.15.1.501, following completion of the activities described in paragraph 3 of this Attachment A. 

  

	 	9.	 Fibrocell may in the future request that Precigen provide, and to the extent that Precigen agrees, Precigen may
provide additional Precigen internal personnel’s time in support of further veledimex manufacturing activities not described above. To the extent that such additional support is provided, such will be provided under terms consistent with the
intellectual property and data rights terms of the ECC and at full cost reimbursement to Precigen (including for both third party costs and Precigen FTE) Fibrocell. Fibrocell has indicated a preliminary interest in possibly pursuing a low dose
clinical batch in the future. Current drug substance batch – 4157.E.15.1.501 expires April 27, 2020. There is no option to extend this expiration date beyond this date for future clinical use, but this expiring batch may potentially be
used for development activities of the pediatric dose. In order to manufacture another unique batch of low dose veledimex for Fibrocell, the Parties would need to conduct due diligence activities for Steps 1-3
for Route B Chemistry, obtain starting material synthesis proposals, and initiate technology transfer activities upon vendor selection, at which time manufacture of a new batch of drug substance will take approximately 18 months and have the
following projected third party costs: 

  

					
		  	a. Starting Materials	  	 100,000Euros (estimated)

		  	b. Step 1-3 Tech Transfer	  	 600,000Euros (estimated)

		  	c. Step 4	  	 175,000Euros (estimated)

		  	d. ICH Stability	  	 150,000Euros (estimated)

		  	e. Precigen FTEs	  	 12-15FTE months

  
 Page 6 

 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
  

	 	10.	 If Fibrocell elects to pursue the activities described in paragraph 9 of this Attachment A, and at that
time determines that Precigen is the owner or otherwise in possession of documentation not described in this Attachment A but required to complete said activities or to complete said activities without significant additional effort or
expense, Fibrocell will notify Precigen, and Precigen will provide such documentation to Fibrocell to the extent such is reasonable in light of the burden to Precigen and upon reasonable cost reimbursement to Precigen. 

 

	 	11.	 For the purpose of clarity, Fibrocell or its designated affiliates may engage with such parties prior to the
manufacture of drug substance, at their own cost, to develop new tableting methods for lower dose concentrations or similar required for the FCX-013 trial, with such decision to be made solely by Fibrocell or
its designated affiliates. 

  

	 	12.	 Upon completion of Precigen’s drug product and drug substance manufacturing support activities under this
Attachment A consistent with the provisions of paragraph 6(a) above relating to the handling of and operations under third party contracts, Precigen will assist Fibrocell in transferring any CRO/CMO contractual relationships to Fibrocell
solely to the extent that such relationships relate to vector stability programs or manufacturing programs for the Retained Products. 

  

	 	13.	 Precigen will provide to Fibrocell upon reasonably request, and only in such cases as Precigen has not already
done so or Fibrocell otherwise already does not have such, the following existing documentation related to the FCX-007 and FCX-013 (to the extent in Precigen’s
possession or control) for a BLA submission: 

  

	 	1.	 Nomenclature 

  

	 	2.	 Structure 

  

	 	3.	 General Properties 

  

	 	4.	 Manufacturers 

  

	 	5.	 Description of the Manufacturing Process 

 

	 	6.	 Control of Materials 

 

	 	7.	 Control of Critical Steps and Intermediates 

 

	 	8.	 Process Validation and/or Evaluation 

 

	 	9.	 Manufacturing Process Development 

 

	 	10.	 Elucidation of Structure and Other Characteristics 

 

	 	11.	 Impurities 

  

	 	12.	 Drug Substance Specification 

 

	 	13.	 Analytical Procedures 

 

	 	14.	 Validation of Analytical Procedures 

 

	 	15.	 Batch Analyses 

  

	 	16.	 Justification of Specification 

 

	 	17.	 Reference Standards or Materials 

 

	 	18.	 Container Closure System 

 

	 	19.	 Stability Summary and Conclusions 

  
 Page 7 

 

 
 20374 Seneca Meadows Pkwy 

Germantown, MD 20876 
 (+1) 301 556 9900 

precigen.com 
  

	 	20.	 Postapproval Stability Protocol and Stability Commitment – Needed for BLA only 

 

	 	21.	 Stability Data 

  

	 	14.	 Upon completion of the items in paragraphs 2-6, 8, 12 and 13 of this
Attachment A, Precigen’s obligations under this Attachment A shall be complete. 

  
 Page 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]